Allarity Therapeutics (ALLR) AI Stock Analysis

• Market Cap: $15.53M
• Dividend Yield: N/A
• Average Volume (3M): 989.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: N/A
• EPS Growth: 99.43%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 15,079,572
• 10 Day Avg. Volume: 601,440
• 30 Day Avg. Volume: 989,539
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.12
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 28 Underperform
• Price Target: ―

Allarity Therapeutics' overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.

Allarity Therapeutics Business Overview & Revenue Model

Company Description

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Allarity Therapeutics, Inc. generates revenue primarily through strategic partnerships and licensing agreements with other pharmaceutical companies. These collaborations often involve upfront fees, milestone payments, and royalties on future sales of licensed products. The company's revenue model is heavily dependent on advancing its clinical pipeline and securing partnerships for drug development and commercialization. Additionally, Allarity may receive funding through grants and research collaborations aimed at supporting its innovative DRP technology and associated drug development efforts.

Allarity Therapeutics Financial Statement Overview

Summary

Allarity Therapeutics, Inc. faces significant financial challenges with persistent losses and cash flow deficits. While recent equity improvements and low leverage are positive, the company's inability to generate sustainable revenue and positive cash flow presents a risk to its financial health.

Income Statement

The company shows a consistent pattern of operating losses with negative EBIT and EBITDA margins over the years, indicating challenges in achieving profitability. However, the gross profit margin for TTM is high at 89.29%, but this is overshadowed by the high net loss. The revenue growth rate is not applicable due to inconsistent revenue figures over the years.

Balance Sheet

The balance sheet reflects instability with a fluctuating stockholders' equity, turning negative in 2023 and back positive in TTM. The debt-to-equity ratio is relatively low in TTM, suggesting low leverage, but past equity deficits highlight financial risks. The equity ratio is reasonable at 63.62% in TTM, indicating some level of asset financing through equity.

Cash Flow

The cash flow statement indicates high operating cash outflows, although recent financing activities helped maintain liquidity. The free cash flow growth rate is negative, highlighting challenges in generating positive cash flows. The operating cash flow to net income ratio is not favorable due to negative net income.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
112.00K	0.00	0.00	0.00	0.00	120.00K
	Gross Profit
100.00K	-37.00K	-120.00K	-106.00K	-86.00K	120.00K
	EBIT
-24.80M	-17.93M	-34.46M	-26.56M	-9.23M	-17.61M
	EBITDA
-18.66M	-12.08M	-17.24M	-25.91M	-6.01M	-15.58M
	Net Income Common Stockholders
-19.35M	-11.90M	-16.06M	-26.65M	-5.07M	-14.40M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.28M	166.00K	2.03M	19.55M	298.00K	1.52M
	Total Assets
1.36M	11.86M	14.54M	49.63M	33.40M	31.61M
	Total Debt
0.00	1.30M	3.73M	1.09M	1.79M	963.00K
	Net Debt
―	1.13M	1.71M	-18.47M	1.49M	-561.00K
	Total Liabilities
12.87K	14.61M	12.65M	30.85M	6.55M	10.70M
	Stockholders Equity
1.34M	-2.75M	1.89M	18.78M	26.85M	18.09M
Cash Flow		Free Cash Flow
-15.82M	-12.74M	-16.84M	-15.05M	-7.25M	-10.12M
	Operating Cash Flow
-15.82M	-12.74M	-16.82M	-15.05M	-7.25M	-10.11M
	Investing Cash Flow
116.00K	0.00	791.00K	1.00M	-3.00K	229.00K
	Financing Cash Flow
33.08M	10.99M	-1.31M	33.82M	6.03M	11.20M

Allarity Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLR, the sentiment is Negative. The current price of 1.03 is below the 20-day moving average (MA) of 1.07, above the 50-day MA of 0.98, and below the 200-day MA of 1.68, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 49.95 is Neutral, neither overbought nor oversold. The STOCH value of 60.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALLR.

Allarity Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.03	-43.89%	2.83%	16.75%	-0.06%
SLGL	51 Neutral	$21.41M	―	-49.39%	―	473.46%	62.25%
LPCN	48 Neutral	$19.15M	650.59	-24.89%	―	10081.34%	―
BIVI	38 Underperform	$19.12M	―	-93.23%	―	―	66.72%
CLDI	37 Underperform	$13.05M	―	354.78%	―	―	64.19%
EDSA	35 Underperform	$13.76M	―	-58.78%	―	―	-126.54%
ALLR	28 Underperform	$15.53M	―	-383.73%	―	―	99.43%

Allarity Therapeutics Corporate Events

Allarity Therapeutics Restructures Board of Directors

On April 16, 2025, Allarity Therapeutics, Inc. restructured its Board of Directors to achieve a more balanced membership among its classes by moving Thomas H. Jensen from Class I to Class III. This change was made to ensure continuity in board service, with Mr. Jensen’s term now expiring in 2028. Additionally, the company announced that its 2025 annual meeting of stockholders will be held on June 13, 2025, with a record date set for April 16, 2025. The meeting date was advanced by more than 30 days from the previous year’s anniversary, prompting the company to file a Current Report to inform stockholders and outline the submission deadlines for stockholder proposals and nominations.

Spark’s Take on ALLR Stock

According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.

Allarity Therapeutics faces substantial financial challenges, with no revenue and consistent operational losses, which weigh heavily on its stock score. Technical indicators provide a neutral outlook without strong trends, and valuation is difficult due to negative earnings. These factors combine to result in a low score, highlighting significant risks for investors.

To see Spark’s full report on ALLR stock, click here.